Official websites use. Share sensitive information only on official, secure websites. The members of the Study Group are listed in the Acknowledgements.
The impact of the most recent advances, including targeted therapies and immune checkpoint inhibitors, on early 3-month mortality in lung cancer is unknown. The aims of this study were to evaluate the real-world rate of and risk factors for early mortality, as well as trends in early mortality over the last 20 years. The KBP prospective observational multicenter studies have been conducted every 10 years since These studies collect data on all newly diagnosed patients with lung cancer all stages and histologies over 1 year in non-academic public hospital pulmonology or oncology units in France.
In this study, we analyzed data on patient and tumor characteristics from participants in the KBP cohort and compared the characteristics of patients who died within 3 months of diagnosis with those of all other patients within the cohort. Overall, patients from 82 centers were included in the KBP cohort. Three-month survival data were available for patients, of whom The overall 3-month mortality rate was found to have decreased significantly over the last 20 years, from Early mortality among patients with lung cancer has significantly decreased over the last 20 years which may reflect recent improvements in treatments.
However, early mortality remained extremely high in , particularly when viewed in light of improvements in longer-term survival. Delays in lung cancer diagnosis and management could contribute to this finding. Key words: early mortality, lung cancer, mortality rate, non-small-cell lung cancer, risk factor.
Of patients with lung cancer included in the KBP study, Early mortality in LC patients has decreased significantly over the last 20 years but remained extremely high in Risk factors for 3-month mortality were similar to those reported in other studies.
